# OnCo record epoetin-beta (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/epoetin-beta/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "epoetin-beta" ;
  schema:name "Epoetin beta"@en ;
  schema:alternateName "epoetin beta"@en, "NeoRecormon"@en, "NeoRecormon" ;
  schema:description "NeoRecormon is a man-made copy of erythropoietin, the hormone that tells the marrow to make red blood cells. In cancer care it treats anaemia that is causing symptoms in adults having chemotherapy for cancers that do not start in the marrow's myeloid cells."@en ;
  schema:url <https://onco.cc/drugs/epoetin-beta/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.ema.europa.eu/en/medicines/human/EPAR/neorecormon> ;
  onco:status "approved" ;
  onco:tag "universe-gap", "ema-register", "supportive" ;
  onco:modality "Recombinant erythropoietin (erythropoiesis-stimulating agent)" ;
  onco:approval "EU 1997: Symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy; anaemia of chronic renal failure; autologous blood pre-donation" ;
  onco:related <https://onco.cc/drugs/epoetin-alfa/>, <https://onco.cc/drugs/epoetin-theta/>, <https://onco.cc/drugs/darbepoetin-alfa/> ;
  onco:technologies <https://onco.cc/technologies/transfusion-support/> ;
  onco:targets <https://onco.cc/targets/epor/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/anaemia/> .